FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587629215> ?p ?o ?g. }

• W2587629215 abstract "Abstract Abstract 1357 Introduction: High dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) is historically effective treatment for patients with relapsed follicular lymphoma (FL) but relapse is common possibly due to contaminated stem cell grafts or inadequate eradication of primary disease. The addition of immunotherapy to HDT/ASCT may augment “in vivo” graft purging and achieve more effective eradication of minimal residual disease (MRD) post ASCT. This may lead to improved PFS and OS. Methods: We conducted 3 sequential prospective phase 2 trials of HDT/ASCT combined with immunotherapy in patients with relapsed FL from 1997–2010. Protocol 1 (n=13) used a-interferon 3 MU/m2 SC TIW for 2 years post ASCT. Protocol 2 (n=23) used a single infusion of rituximab (R) 375 mg/m2 for ‘in vivo’ purging 3–5 days pre-stem cell collection and 2 sets of 4 weekly R at 2 and 6 months post ASCT respectively. Protocol 3 (n=32) used 3 infusions of R 375 mg/m2 pre stem cell collection, followed by a-interferon 3 MU/m2 SC TIW × 2 years + R 375mg/m2 × 6 weekly infusions post ASCT. Eligibility included adult patients age 18–65 with stage III or IV follicular lymphoma grades 1–3a in first or second relapse. Salvage chemotherapy was either CHOP or DHAP depending on prior anthracycline exposure. High dose therapy was cyclophosphamide, carmustine, and etoposide (CBV). Minimal residual disease (MRD) assessment of t(14; 18) by quantitative PCR was serially performed in blood, PBSC and marrow. Studies were REB approved and all patients gave informed consent. Results: Sixty-eight patients from the 3 trials are included. Median age at study enrolment was 47 (30-71) and patients were a median of 31 mo (9-197) from diagnosis. 54% were male. Median FLIPI score was 2. Median # of prior chemotherapies was 1. Median number of cycles of salvage chemotherapy was 4 (2 - 10). 63 patients proceeded to ASCT. 5 patients were not transplanted either do to disease progression (2), or failed stem cell mobilization (3). Baseline characteristics of the patients enrolled in the three trials were similar, with the exception of rituximab(R) exposure in 22% of the patients in Protocol 3. 4 (6%) patients were lost to follow up. Median time to death or last follow was 84.5 mo (7-166). 32 patients (47%) relapsed and 20 (29%) have died. Median follow up times for each trial were 116, 99 and 57 mo. Actuarial median OS for Protocol 1 was 136 mo from enrolment and has not yet been reached for Protocols 2 and 3. Actuarial median PFS for Protocols 1 and 3 are 49 and 78 mo respectively and has not yet been reached for Protocol 2. MRD assessment by PCR was collected on 48 patients. Compared with study 1, the increased use of R pre SC collection improved in vivo purging by 2 logs. In Protocols 1 and 2, most still had detectable disease in the graft to a sensitivity of 1 cell/100,000. In Protocol 3, 56% had MRD negative apheresis products. 91% of 46 evaluable patients achieved molecular remission post stem cell transplant. Thirteen patients (19%) developed secondary malignancies post ASCT with a median time to malignancy of 88.5 mo (39-144). 1 patient developed 2 distinct malignancies. Secondary malignancies present were: MDS (4), AML (1), ALL (1), basal cell carcinoma (2), squamous cell carcinoma (3), thyroid cancer (1), non small cell lung cancer (1) and adenocarcinoma of unknown origin (1). Five (7%) patients transformed to DLBCL, with a median time to transformation post ASCT of 43.5 mo (17-142). The majority of patients who received rituximab immunotherapy pre and post ASCT developed persistent hypogammaglobulinemia. 17 patients (26%) developed interstitial pneumonitis or >2 respiratory complications post rituximab. 4 patients (6%) require monthly IVIG to treat recurrent respiratory infections. 10 patients (15%) developed herpes zoster <90 days post ASCT. 15% and 30% of patients in Protocols 1 and 3 did not complete the 2 years of alpha-IFN post ASCT secondary to one or more of depression, fatigue or cytopenias. Conclusion: HDT + ASCT combined with R +/− a-IFN produces durable PFS and molecular remissions but is associated with prolonged hypogammaglobulinemia and higher rates of interstitial pneumonitis. Three infusions of R pre SC collection achieve higher rates of molecular remission. Compliance with 2 years of a-IFN added to R post ASCT is poor and may not add clinical benefits to R alone. The additional role of HDT/ASCT in the era of R-chemotherapy for FL needs to be explored. Disclosures: No relevant conflicts of interest to declare." @default.
• W2587629215 created "2017-02-17" @default.
• W2587629215 creator A5007576393 @default.
• W2587629215 creator A5018929375 @default.
• W2587629215 creator A5024269299 @default.
• W2587629215 creator A5027219979 @default.
• W2587629215 creator A5032098740 @default.
• W2587629215 creator A5044632878 @default.
• W2587629215 creator A5056927977 @default.
• W2587629215 creator A5061856914 @default.
• W2587629215 creator A5064774673 @default.
• W2587629215 creator A5066002175 @default.
• W2587629215 creator A5069659959 @default.
• W2587629215 creator A5070115729 @default.
• W2587629215 creator A5089147149 @default.
• W2587629215 date "2010-11-19" @default.
• W2587629215 modified "2023-09-27" @default.
• W2587629215 title "The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions" @default.
• W2587629215 doi "https://doi.org/10.1182/blood.v116.21.1357.1357" @default.
• W2587629215 hasPublicationYear "2010" @default.
• W2587629215 type Work @default.
• W2587629215 sameAs 2587629215 @default.
• W2587629215 citedByCount "1" @default.
• W2587629215 countsByYear W25876292152016 @default.
• W2587629215 crossrefType "journal-article" @default.
• W2587629215 hasAuthorship W2587629215A5007576393 @default.
• W2587629215 hasAuthorship W2587629215A5018929375 @default.
• W2587629215 hasAuthorship W2587629215A5024269299 @default.
• W2587629215 hasAuthorship W2587629215A5027219979 @default.
• W2587629215 hasAuthorship W2587629215A5032098740 @default.
• W2587629215 hasAuthorship W2587629215A5044632878 @default.
• W2587629215 hasAuthorship W2587629215A5056927977 @default.
• W2587629215 hasAuthorship W2587629215A5061856914 @default.
• W2587629215 hasAuthorship W2587629215A5064774673 @default.
• W2587629215 hasAuthorship W2587629215A5066002175 @default.
• W2587629215 hasAuthorship W2587629215A5069659959 @default.
• W2587629215 hasAuthorship W2587629215A5070115729 @default.
• W2587629215 hasAuthorship W2587629215A5089147149 @default.
• W2587629215 hasConcept C126322002 @default.
• W2587629215 hasConcept C141071460 @default.
• W2587629215 hasConcept C143998085 @default.
• W2587629215 hasConcept C2777058707 @default.
• W2587629215 hasConcept C2778461978 @default.
• W2587629215 hasConcept C2779050716 @default.
• W2587629215 hasConcept C2779338263 @default.
• W2587629215 hasConcept C2779823535 @default.
• W2587629215 hasConcept C2780653079 @default.
• W2587629215 hasConcept C2911091166 @default.
• W2587629215 hasConcept C71924100 @default.
• W2587629215 hasConcept C90924648 @default.
• W2587629215 hasConceptScore W2587629215C126322002 @default.
• W2587629215 hasConceptScore W2587629215C141071460 @default.
• W2587629215 hasConceptScore W2587629215C143998085 @default.
• W2587629215 hasConceptScore W2587629215C2777058707 @default.
• W2587629215 hasConceptScore W2587629215C2778461978 @default.
• W2587629215 hasConceptScore W2587629215C2779050716 @default.
• W2587629215 hasConceptScore W2587629215C2779338263 @default.
• W2587629215 hasConceptScore W2587629215C2779823535 @default.
• W2587629215 hasConceptScore W2587629215C2780653079 @default.
• W2587629215 hasConceptScore W2587629215C2911091166 @default.
• W2587629215 hasConceptScore W2587629215C71924100 @default.
• W2587629215 hasConceptScore W2587629215C90924648 @default.
• W2587629215 hasLocation W25876292151 @default.
• W2587629215 hasOpenAccess W2587629215 @default.
• W2587629215 hasPrimaryLocation W25876292151 @default.
• W2587629215 hasRelatedWork W1969994327 @default.
• W2587629215 hasRelatedWork W2030447348 @default.
• W2587629215 hasRelatedWork W2099626767 @default.
• W2587629215 hasRelatedWork W2116029073 @default.
• W2587629215 hasRelatedWork W2395971691 @default.
• W2587629215 hasRelatedWork W2416574895 @default.
• W2587629215 hasRelatedWork W2514891680 @default.
• W2587629215 hasRelatedWork W2525286438 @default.
• W2587629215 hasRelatedWork W2530583073 @default.
• W2587629215 hasRelatedWork W2558283135 @default.
• W2587629215 hasRelatedWork W2559248048 @default.
• W2587629215 hasRelatedWork W2560035791 @default.
• W2587629215 hasRelatedWork W2560182095 @default.
• W2587629215 hasRelatedWork W2563579049 @default.
• W2587629215 hasRelatedWork W2568971600 @default.
• W2587629215 hasRelatedWork W2576281162 @default.
• W2587629215 hasRelatedWork W2580740860 @default.
• W2587629215 hasRelatedWork W2591022778 @default.
• W2587629215 hasRelatedWork W3044174034 @default.
• W2587629215 hasRelatedWork W3198754129 @default.
• W2587629215 isParatext "false" @default.
• W2587629215 isRetracted "false" @default.
• W2587629215 magId "2587629215" @default.
• W2587629215 workType "article" @default.